Breaking News Instant updates and real-time market news.

NVTA

Invitae

$22.80

-0.065 (-0.28%)

, UNH

UnitedHealth

$227.14

5.4 (2.44%)

08:02
04/23/19
04/23
08:02
04/23/19
08:02

UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark

Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.

NVTA

Invitae

$22.80

-0.065 (-0.28%)

UNH

UnitedHealth

$227.14

5.4 (2.44%)

NEO

NeoGenomics

$20.00

0.33 (1.68%)

LH

LabCorp

$144.26

-0.94 (-0.65%)

DGX

Quest Diagnostics

$85.17

-0.55 (-0.64%)

OPK

Opko Health

$2.33

-0.075 (-3.13%)

  • 23

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 14

    May

  • 28

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 05

    Jun

  • 23

    Jun

  • 06

    Aug

  • 13

    Nov

NVTA Invitae
$22.80

-0.065 (-0.28%)

03/04/19
CHDN
03/04/19
INITIATION
Target $29
CHDN
Buy
Invitae initiated with a Buy at Chardan
Chardan analyst Steven Wardell initiated Invitae with a Buy and $29 price target. Wardell said Invitae is the cost and quality leader in the genetic testing market with a centralized testing and data strategy that positions the company to compete in this large, and attractive market. The analyst expects strong topline growth over the next three years and likes management's ability to execute and their confidence on where the sector is going and their place in it. He believes shares are mispriced versus peers given it is a growth leader among high-growth digital health companies.
03/04/19
03/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with an Outperform at SVB Leerink. 2. Invitae (NVTA) initiated with a Buy at Chardan. 3. Immunomedics (IMMU) initiated with a Buy at H.C. Wainwright. 4. Canopy Growth (CGC) initiated with a Neutral at Melius Research. 5. Alector (ALEC) initiated with an Overweight at Morgan Stanley and Barclays, an Outperform at SVB Leerink and Cowen, as well as a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/08/19
OPCO
04/08/19
NO CHANGE
Target $30
OPCO
Outperform
Invitae price target raised to $30 from $21 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Invitae to $30 from $21 based on improved long-term competitive positioning for the company's patient-initiated testing given data presented at the ACMG meeting demonstrating poor performance for a leading DTC genetic test and potential consolidation in DTC market as industry matures and economies of scale, quality/clinical data and regulatory oversight drive market share. The analyst reiterates an Outperform rating on the shares.
02/20/19
BNCH
02/20/19
NO CHANGE
Target $20
BNCH
Buy
Invitae price target raised to $20 from $17 at Benchmark
Benchmark analyst Bruce Jackson raised his 2019 and 2020 revenue estimates for Invitae after the company released 4Q results and 2019 guidance. Given his higher estimates, Jackson increased his price target on Invitae shares to $20 from $17 and keeps a Buy rating on the shares.
UNH UnitedHealth
$227.14

5.4 (2.44%)

04/23/19
UBSW
04/23/19
INITIATION
Target $238
UBSW
Neutral
UnitedHealth initiated with a Neutral at UBS
UBS analyst Whit Mayo started UnitedHealth with a Neutral rating and $238 price target, saying its sector is "dominated by exogenous factors" such as the election, policy uncertainty, and a pending ACA litigation. The analyst notes that the stock has more upside than downside in the near term, but also believes that the Street consensus has priced in UnitedHealth's long-term growth and the trend of not having missed on its numbers in 10 years.
04/18/19
LEER
04/18/19
NO CHANGE
LEER
Medicare-For-All risk overblown, investors should buy MCOs, says SVB Leerink
SVB Leerink analyst Ana Gupte believes Medicare-For-All risk is overblown, not the same as 2008/09, and recommends investors step in now to buy MCOs. The analyst believes it is a "once in a decade opportunity" to get high quality names at these depressed multiples, with UnitedHealth (UNH), Anthem (ANTM), and Humana (HUM) being her favorites.
04/17/19
RBCM
04/17/19
NO CHANGE
Target $83
RBCM
Outperform
eHealth selloff not related to company specific news, says RBC Capital
RBC Capital analyst Frank Morgan says he's found no company specific news that would explain the weakness today in shares of eHealth. Rather, the analyst attributes the 22% pullback to continued selling in managed care operators and providers, which began yesterday morning. He attributes yesterday's sell-off to Democratic presidential candidate rhetoric around Medicare-for-All, including a tweet from candidate Bernie Sanders during UnitedHealth's Q1 earnings call advocating for MFA. Morgan believes investors were looking to take profits in any strong year-to-date performers, like eHealth. The analyst has an Outperform rating on the stock with an $83 price target. eHealth in afternoon trading is down 22%, or $14.05, to $51.38.
04/17/19
JPMS
04/17/19
NO CHANGE
Target $235
JPMS
Neutral
JPMorgan lowers UnitedHealth target to $235 on 'sustainable' political risk
JPMorgan analyst Gary Taylor last night lowered his price target for UnitedHealth to $235 from $301 following the company's Q1 earnings report. The reduction is due to "renewed and sustainable Election year political risk," particularly around leading Democrats' plans for single-payor Medicare-For-All plans, Taylor tells investors in a research note. The analyst, however, does not believe UnitedHealth said anything fundamentally negative on the earnings call to justify the corresponding stock selloff. The analyst attributes the reversal in trading yesterday's to renewed and continuing Medicare-For-All political fears. He keeps an Overweight rating on shares of UnitedHealth. The stock in morning trading is down 3%, or $7.64, to $213.32.
NEO NeoGenomics
$20.00

0.33 (1.68%)

01/03/19
NEED
01/03/19
INITIATION
Target $14
NEED
Buy
NeoGenomics initiated with a Buy at Needham
Needham analyst Stephen Unger started NeoGenomics with a Buy rating and $14 price target.
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
03/29/19
NEED
03/29/19
NO CHANGE
Target $22
NEED
Buy
NeoGenomics price target raised to $22 from $19 at Needham
Needham analyst Stephen Unger raised his price target on NeoGenomics to $22 and kept his Buy rating after meeting with its CEO Doug VanOort. The analyst says the discussions left him "incrementally bullish" about the company's prospects driven by the doubling of its sales force to 70 representatives that could potentially increase its test volumes. Unger adds that the company's integration of Genoptix is proceeding as planned with no negative surprises, and the "development of a testing panel using next-generation sequencing remains on track for FDA submission before the end of 2019."
03/12/19
FANA
03/12/19
NO CHANGE
Target $23
FANA
Strong Buy
NeoGenomics target raised to $23 after company visit at First Analysis
First Analysis analyst Joseph Munda raised his price target for NeoGenomics to $23 from $22 and reiterates a Strong Buy rating on the shares after visiting the company's headquarters. The analyst says a "deep dive" with management on the integration of Genoptix and the pharma services business "raised his conviction level" for the shares. NeoGenomics offers a "one-stop oncology testing shop" that is well positioned to scale its pharma services business and continue to take clinical testing market share, Munda tells investors in a research note.
LH LabCorp
$144.26

-0.94 (-0.65%)

04/02/19
JEFF
04/02/19
UPGRADE
JEFF
Buy
LabCorp upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Tanquilut upgraded Quest Diagnostics to Buy from Hold.
04/02/19
WOLF
04/02/19
INITIATION
Target $150
WOLF
Underperform
LabCorp initiated with an Underperform at Wolfe Research
Wolfe Research started LabCorp with an Underperform rating and $150 price target, citing concerns about the 2021 impact of PAMA and exposure to patient collections.
04/02/19
04/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exelon (EXC) upgraded to Outperform from Market Perform at Wells Fargo with analyst Neil Kalton saying a key tenant to his thesis is that ExGen's nuclear fleet operates through the end of the units' various license extension periods, which will likely require additional policy support. 2. CommScope (COMM) upgraded to Outperform from Neutral at Credit Suisse with analyst Sami Badri citing fundamental strength in the combined business computed in his updated CommScope-Arris (ARRS) merger model with the Arris acquisition expected to close in April 2019. 3. Quest Diagnostics (DGX) and LabCorp (LH) upgraded to Buy from Hold at Jefferies. 4. Hostess Brands (TWNK) upgraded to Buy from Hold at Deutsche Bank with analyst Rob Dickerson saying management execution, a turnaround to profitability in the Chicago bakery and improved pricing could return Hostess to "top-tier revenue growth" this year. 5. Amphenol (APH) upgraded to Buy from Hold at SunTrust with analyst William Stein saying in a world of uncertainty, Amphenol offers more dependable upside. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/02/19
JEFF
04/02/19
UPGRADE
Target $107
JEFF
Buy
Quest, LabCorp upgraded to Buy ahead of UnitedHealth lab network rollout
Jefferies analyst Brian Tanquilut upgraded both Quest Diagnostics (DGX) and Laboratory Corp. of America (LH) to Buy from Hold on the belief that UnitedHealth's (UNH) rollout on July 1 of its preferred lab network will be a positive catalyst for both stocks. Quest and LabCorp's likely inclusion should bolster their organic growth beginning in 2020, Tanquilut tells investors in a research note. The analyst finds both stocks "compelling" with their 2019 outlooks "seemingly de-risked with fairly conservative guidance ranges" and 2020 consensus estimates "looking conservative." Further, Quest's and LabCorp's valuations are at below-historical relative averages, Tanquilut contends. The analyst raised his price target for Laboratory Corp. to $190 from $154 and for Quest to $107 from $93.
DGX Quest Diagnostics
$85.17

-0.55 (-0.64%)

04/02/19
WOLF
04/02/19
INITIATION
WOLF
Underperform
Quest Diagnostics initiated with an Underperform at Wolfe Research
Wolfe Research started Quest Diagnostics with an Underperform rating and $83 price target, citing concerns about the 2021 impact of PAMA and the view that almost all of its free cash flow is "spoken for" over the next few years.
04/02/19
JEFF
04/02/19
UPGRADE
JEFF
Buy
Quest Diagnostics upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Gil Tanquilut upgraded Quest Diagnostics to Buy from Hold.
OPK Opko Health
$2.33

-0.075 (-3.13%)

11/12/18
BRRR
11/12/18
NO CHANGE
Target $7
BRRR
Outperform
Opko Health risk/reward favorable after 'mixed' Q3, says Barrington
Barrington analyst Michael Petusky keeps an Outperform rating on Opko Health with a $7 price target following the company's "mixed" Q3 results. Revenues were light, but good expense management drove a slight earnings beat, Petusky tells investors in a post-earnings research note. The Novitas decision to draft non-coverage guidance for Opko's diagnostic for aggressive prostate cancer, 4Kscore, may now be providing a slight headwind to the company's results, the analyst contends. Nonetheless, he believes the stock's risk/reward continues to favor investment.
03/15/19
JEFF
03/15/19
UPGRADE
Target $5
JEFF
Buy
Opko Health assumed with a Buy from Hold at Jefferies
Jefferies analyst Maury Raycroft assumed coverage of Opko Health and upgraded the shares to Buy from Hold. The analyst raised his price target for the stock to $5 from $4. The company had a rough 2018, and though some headwinds may still be ahead, the "terrain gets a little smoother and more interesting in 2019." Raycroft tells investors in a research note. He sees the oxyntomodulin Phase IIb data by end of March as the next catalyst and does not believe the Street is focused on this program. Further, Rayaldee dialysis data by the end of 2019 "could put the drug on a different level commercially," says Raycroft.
02/01/19
BRRR
02/01/19
NO CHANGE
Target $7
BRRR
Outperform
Barrington lowers Opko revenue estimate by $15M for 4Kscore news
Novitas Solutions, Opko Health's Medicare Administrative Contractor, has followed through on its initial non-coverage determination for 4Kscore issued in May 2018 and has communicated its intention to stop reimbursing for the test as of March 20, 2019, Barrington analyst Michael Petusky tells investors in a research note. Opko has spent the past eight months trying to communicate the value of 4Kscore to Novitas "and has clearly fallen short in this effort," says Petusky. The analyst, who "highly" doubts this decision will be reversed "any time soon," believes in the value of the test based on experts he's heard weigh in on the issue. The news is very disappointing, but Opko will continue to have some near-term opportunity to continue to educate commercial payors and perhaps get some "wins," Petusky writes. He reduced his annual revenue estimate for 4Kscore contribution by about $15M and keeps an Outperform rating on Opko Health with a $7 price target.
02/28/19
BRRR
02/28/19
NO CHANGE
Target $5
BRRR
Outperform
Opko Health risk/reward still favors investment, says Barrington
Barrington analyst Michael Petusky lowered his price target for Opko Health to $5 from $7 after the company's Q4 revenue missed his estimate and Q1 guidance came in less than expected. The analyst, however, maintains an Outperform rating on the shares. He believes the risk/reward still favors investment.

TODAY'S FREE FLY STORIES

NXST

Nexstar

$102.01

-1.18 (-1.14%)

, TRCO

Tribune Media

$46.66

(0.00%)

05:43
09/20/19
09/20
05:43
09/20/19
05:43
Conference/Events
Nexstar to host conference call »

Conference call to…

NXST

Nexstar

$102.01

-1.18 (-1.14%)

TRCO

Tribune Media

$46.66

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 13

    Nov

SMTX

SMTC Corp.

$2.96

0.16 (5.71%)

05:35
09/20/19
09/20
05:35
09/20/19
05:35
Conference/Events
SMTC Corp. to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 12

    Nov

ENLAY

Enel

$0.00

(0.00%)

05:32
09/20/19
09/20
05:32
09/20/19
05:32
Upgrade
Enel rating change  »

Enel upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$36.17

-1.075 (-2.89%)

05:31
09/20/19
09/20
05:31
09/20/19
05:31
Downgrade
Synovus rating change  »

Synovus downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

W

Wayfair

$128.67

-3.065 (-2.33%)

05:29
09/20/19
09/20
05:29
09/20/19
05:29
Initiation
Wayfair initiated  »

Wayfair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYL

Xylem

$77.99

-0.41 (-0.52%)

05:29
09/20/19
09/20
05:29
09/20/19
05:29
Initiation
Xylem initiated  »

Xylem initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 31

    Oct

PRDSY

Prada

$0.00

(0.00%)

05:28
09/20/19
09/20
05:28
09/20/19
05:28
Downgrade
Prada rating change  »

Prada downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURBY

Burberry

$0.00

(0.00%)

05:27
09/20/19
09/20
05:27
09/20/19
05:27
Upgrade
Burberry rating change  »

Burberry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

05:26
09/20/19
09/20
05:26
09/20/19
05:26
Upgrade
J Sainsbury rating change  »

J Sainsbury upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$10.45

0.095 (0.92%)

05:25
09/20/19
09/20
05:25
09/20/19
05:25
Initiation
Freeport McMoRan initiated  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

ANFGY

Antofagasta

$0.00

(0.00%)

05:23
09/20/19
09/20
05:23
09/20/19
05:23
Downgrade
Antofagasta rating change  »

Antofagasta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRC

AtriCure

$26.02

0.22 (0.85%)

05:21
09/20/19
09/20
05:21
09/20/19
05:21
Recommendations
AtriCure analyst commentary  »

AtriCure one of the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$10.50

-0.54 (-4.89%)

05:19
09/20/19
09/20
05:19
09/20/19
05:19
Recommendations
Neuronetics analyst commentary  »

Piper calls Neuronetics a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FGEN

FibroGen

$39.69

-1.3 (-3.17%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

05:16
09/20/19
09/20
05:16
09/20/19
05:16
Hot Stocks
FibroGen, Astellas Pharma announce Japanese approval of Evrenzo »

FibroGen (FGEN) and…

FGEN

FibroGen

$39.69

-1.3 (-3.17%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

VOPKY

Koninklijke Vopak

$0.00

(0.00%)

05:16
09/20/19
09/20
05:16
09/20/19
05:16
Upgrade
Koninklijke Vopak rating change  »

Koninklijke Vopak…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYA

Liberty Global

$27.09

-0.25 (-0.91%)

05:12
09/20/19
09/20
05:12
09/20/19
05:12
Downgrade
Liberty Global rating change  »

Liberty Global downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 07

    Nov

HRI

Herc Holdings

$45.32

-1.615 (-3.44%)

, URI

United Rentals

$125.06

0.415 (0.33%)

05:06
09/20/19
09/20
05:06
09/20/19
05:06
Upgrade
Herc Holdings, United Rentals rating change  »

Herc Holdings upgraded to…

HRI

Herc Holdings

$45.32

-1.615 (-3.44%)

URI

United Rentals

$125.06

0.415 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

URI

United Rentals

$125.06

0.415 (0.33%)

05:03
09/20/19
09/20
05:03
09/20/19
05:03
Upgrade
United Rentals rating change  »

United Rentals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SUZ

Suzano

$15.97

-0.43 (-2.62%)

04:59
09/20/19
09/20
04:59
09/20/19
04:59
Downgrade
Suzano rating change  »

Suzano downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$133.76

3.97 (3.06%)

, CMCSA

Comcast

$46.68

-0.25 (-0.53%)

04:56
09/20/19
09/20
04:56
09/20/19
04:56
Initiation
Pivotal starts 'dramatically overvalued' Roku with Sell rating, $60 target »

Pivotal Research analyst…

ROKU

Roku

$133.76

3.97 (3.06%)

CMCSA

Comcast

$46.68

-0.25 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

FTCH

Farfetch

$8.91

-0.42 (-4.50%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Cowen retail/luxury analyst to hold an analyst/industry conference call »

Retail & Luxury Goods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FB

Facebook

$190.15

1.96 (1.04%)

, SNAP

Snap

$16.87

-0.04 (-0.24%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

technology and Internet…

FB

Facebook

$190.15

1.96 (1.04%)

SNAP

Snap

$16.87

-0.04 (-0.24%)

TWTR

Twitter

$42.94

-0.29 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

TRGP

Targa Resources

$40.89

-0.725 (-1.74%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Targa Resources management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

IRM

Iron Mountain

$32.15

-0.02 (-0.06%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Iron Mountain management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

LGND

Ligand

$104.62

5.37 (5.41%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Ligand management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 02

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.